Prof Hauschild talks to ecancertv at EADO 2015 about how talimogene laherparepvec (T-VEC) can be used early in melanoma treatment, leaving immunotherapy and targeted therapies for further treatment later. Prof Hauschild also discusses the new licence for the adjuvant use of ipilimumab. He states that it is highly questionable because of high toxicity and extremely high cost. ecancer's filming at EADO 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.